Close menu




July 2nd, 2026 | 07:25 CEST

Caution Advised with Novo Nordisk! TUI Is Making a Comeback! Globex Mining Outperforms Barrick Mining!

  • Mining
  • Commodities
  • PreciousMetals
  • travel
  • Biotechnology
Photo credits: TUI AG

Caution advised with Novo Nordisk! Analysts warn that the pharmaceutical giant is heading toward a patent cliff. As a result, the company could lose billions. Without much fanfare, the stock has gained 30% in recent weeks. What do analysts say? Analysts remain bullish on TUI. The tourism group's stock is recommended as a "Buy". The easing of tensions in the Middle East and falling oil prices are fueling positive sentiment. The summer season will now be decisive. Globex Mining's stock has outperformed Barrick Mining this year. The recent correction offers an attractive entry opportunity to benefit from the commodities boom while diversifying risk.

time to read: 5 minutes | Author: Fabian Lorenz
ISIN: GLOBEX MINING ENTPRS INC. | CA3799005093 | TSX: GMX. OTCQX: GLBXF , TUI AG NA O.N. | DE000TUAG505 , NOVO NORDISK A/S | DK0062498333

Table of contents:


    Globex Mining: Better Than Barrick

    The sell-off in commodity stocks is currently creating interesting buying opportunities. One example is Globex Mining. The stock has fallen from CAD 2.90 in February to its current price of CAD 1.97. Nevertheless, the stock is up 15.2% so far this year. This means it has outperformed, for example, Barrick Mining. And it shows that the risk-diversified business model appears to be working. The Canadian commodities incubator acquires promising commodities projects in established mining regions. The portfolio is broadly diversified across gold, silver, copper, nickel, rare earths, antimony, manganese, and industrial minerals. In addition, the projects are at various stages of development—ranging from early-stage exploration to projects with feasibility studies. The vast majority of these projects are not developed in-house but are assigned to exploration companies through option agreements. In return, Globex Mining receives royalties, milestone payments, or other forms of participation. This allows Globex to benefit from exploration successes without bearing the costs.

    The more than 100 projects generate a steady stream of news. Most recently, progress was reported on the Bell Mountain gold-silver project in the US state of Nevada. According to the operator, Lincoln Gold, the key permits for the project—in which Globex holds a 3% gross metal royalty—have now been secured. Following the completion of an updated feasibility study, Bell Mountain is now in the construction financing phase. Capital expenditures are estimated at USD 25 to USD 30 million plus security deposits, and the construction period is expected to last eight to ten months. The reported resources potentially recoverable via open-pit mining amount to approximately 45,800 ounces of gold equivalent in the Measured and Indicated categories, as well as an additional approximately 27,100 ounces in the Inferred category. Furthermore, there is additional exploration potential to expand the resource.

    It should also be noted that the feasibility study was based on a gold price of USD 1,950 per ounce and a silver price of USD 24 per ounce. Since this is significantly below current market prices, the project's viability could improve if financing is secured.

    Driven by such news, Globex shares should soon start to gain momentum.

    https://youtu.be/EW22N6jb9W4?si=owhcD6ya-1_2JPco

    TUI: Hope for a Strong Summer Season

    At TUI, the comeback appears to be already underway. Over the past two weeks, the tourism group's stock has gained around 10%. Hopes for peace in the Middle East and the falling oil price have put investors in a buying mood. According to analysts at mwb research, the current share price of around EUR 7.24 may not be the end of the story. They believe TUI shares could reach as high as EUR 15.

    From the analysts' perspective, the travel industry has historically recovered quickly following regional conflicts. Since about 45% of summer bookings have not yet been made, last-minute bookings are likely to drive a catch-up effect as uncertainty subsides. TUI posted robust results in the second quarter of 2025/26 despite geopolitical headwinds and weather-related one-time effects. Adjusted EBIT came in at minus EUR 188 million, which was EUR 19 million higher than the prior-year figure and slightly better than market expectations. Adjusted for charges totaling EUR 45 million related to the war in Iran and a hurricane in Jamaica, operating earnings would have actually improved by EUR 64 million. The forecast, which had recently been lowered due to the impact of the war in Iran, was confirmed. For the 2025/26 fiscal year, the Group expects adjusted EBIT of between EUR 1.1 billion and EUR 1.4 billion at constant exchange rates. A revenue forecast remains on hold.

    Analysts believe the 2026 summer season is likely to remain challenging for TUI. Customers are booking at shorter notice, and demand is shifting from the eastern to the western Mediterranean. As of early May, booked revenue in the UK was 10% below the prior-year level, and in Germany, 3% below. TUI is responding by reducing risk capacity by 4% to ensure load factors and earnings quality.

    However, TUI has since reported that demand for Turkey and Egypt is picking up again. Antalya, in particular, has once again moved to the top of the list of summer destinations, followed by Mallorca, Crete, Rhodes, and Kos. Hurghada is also in demand. This marks a return to normal booking patterns following the temporary shift toward the western Mediterranean, while Spain as a whole remains the most popular travel destination among TUI customers. About four-fifths of summer trips within Europe are to the Mediterranean or the Canary Islands.

    Novo Nordisk: Analyst Urges Caution

    Without much fanfare, Novo Nordisk's stock has gained about 40% in value over the past three months. The share is now trading at around DKK 314, or EUR 42. The fact that the stock is still down 5% year-to-date shows just how severe the sell-off was previously. The reason for the recent rally is the success of the weight-loss drug Wegovy in pill form.

    Analysts have recently been more cautious. The pharmaceutical company will release its quarterly results on August 5. Experts expect solid performance, but nothing more. Jefferies raised its price target, but only to DKK 285. As a result, analysts currently view the pharmaceutical company as merely a "Hold". Due to numerous uncertainties in the second half of the year, analysts do not believe that Novo Nordisk will raise its full-year forecast.

    For JPMorgan, Novo Nordisk shares are also not a Buy and are rated "Neutral." The price target is DKK 250.

    In its latest report, Deutsche Bank looks to the future and issues a warning. According to the report, the Danish company could face a patent cliff in 2031, as patents for its blockbuster drugs would expire then. This could potentially reduce the company's revenue by billions. Consequently, analysts do not recommend buying Novo shares, and the price target is set at DKK 290.


    The recent correction in shares of Globex Mining offers an attractive entry opportunity to benefit from the commodities boom while diversifying risk. Novo Nordisk has performed very well in recent weeks. Perhaps the share buyback program launched in June can continue to drive the rally. The performance of TUI shares is likely to remain heavily dependent on external developments. A summer rally cannot be ruled out.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 18th, 2026 | 05:32 CET

    Commodities, Steel and SpaceX: A Look at the Opportunities in Strategic Resources, thyssenkrupp and Singulus

    • Commodities
    • Iron ore
    • Pellets
    • Green steel
    • Vanadium
    • Titanium
    • Solar
    • Opportunities
    • Investments

    A SpaceX order sends Singulus shares soaring. thyssenkrupp is driving forward its transformation into a pure financial holding company by spinning off materials distributor and service provider tk accelis and making the value of its holdings visible on the stock market. Strategic Resources, meanwhile, starts earlier in the industrial value chain. With high-purity iron ore pellets as well as vanadium, iron and titanium, the company aims to position itself as a raw materials supplier for lower-emission steel production and other future applications. Which share will come out ahead next year?

    Read

    Commented by Armin Schulz on November 17th, 2026 | 05:44 CET

    CTS Eventim, Aspermont, SAP – Opportunities in the AI age with tickets, mining data and software

    • CTS Eventim
    • Aspermont
    • Ticket sales
    • digital business
    • Artificial intelligence
    • Specialist publisher
    • Commodities
    • Mining data
    • Marketing agency
    • ERP
    • Business software
    • Cloud
    • Agents
    • SAP

    Artificial intelligence does not hit every business model equally hard. Activist investor Ananym Capital announced its investment in CTS Eventim on October 20 and considers the ticket marketer resilient to AI. Aspermont wants to unlock its 190-year-old mining archive, and ten major mining groups are set to work with it in initial trials from November. Companies wanting to use AI need reliable data. SAP reported on October 21 that contractually committed cloud revenues of EUR 24.1 billion are due over the next 12 months. We therefore take a closer look at CTS Eventim, Aspermont and SAP.

    Read